Format

Send to

Choose Destination
Rheumatology (Oxford). 2018 Jan 1;57(suppl_1):i47-i50. doi: 10.1093/rheumatology/kex432.

Cardiac and renal protective effects of urate-lowering therapy.

Author information

1
Université Paris 7, UFR médicale, Assistance Publique-Hôpitaux de Paris, Hôpital Lariboisière, Fédération de Rhumatologie.
2
INSERM UMR-1132, Hôpital Lariboisière and Université Paris Diderot, Sorbonne Paris Cité, Paris, France.

Abstract

Patients with gout often have co-morbidities such as cardiovascular disease, renal failure and metabolic syndrome components. Some studies, but not all, have suggested that hyperuricaemia and gout are associated with increased risk of myocardial infarction, renal failure and death primarily because of increased risk of cardiovascular events. Therefore, knowledge of the effects of urate-lowering therapy (ULT) on co-morbidities, in particular cardiovascular events and chronic kidney disease, is crucial. Randomized controlled trials (RCTs) have suggested that allopurinol, a xanthine oxidase inhibitor, could improve exercise capacity in patients with chronic stable angina and could decrease blood pressure in adolescents. In contrast, a well-designed RCT found no effect of allopurinol in patients with heart failure. The impact of ULT in patients with chronic kidney disease is unclear. Some RCTs found that allopurinol could slow the decline in kidney function, whereas a recent controlled trial found no benefit of febuxostat. Large randomized placebo-controlled trials are warranted to confirm or not the benefit of ULT on co-morbidities.

KEYWORDS:

allopurinol; co-morbidities; febuxostat; gout; urate-lowering therapy

PMID:
29272510
DOI:
10.1093/rheumatology/kex432
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center